U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C63H111N11O12
Molecular Weight 1214.6219
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of VALSPODAR

SMILES

C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C

InChI

InChIKey=YJDYDFNKCBANTM-QCWCSKBGSA-N
InChI=1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1

HIDE SMILES / InChI

Molecular Formula C63H111N11O12
Molecular Weight 1214.6219
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 11 / 11
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT00002878 | https://clinicaltrials.gov/ct2/show/NCT00002826 | https://clinicaltrials.gov/ct2/show/NCT00004217 | https://clinicaltrials.gov/ct2/show/NCT00006363 | https://www.ncbi.nlm.nih.gov/pubmed/10820137

Valspodar (PSC-833) is a derivative of cyclosporin but devoid of the immunosuppressive and nephrotoxic properties seen in cyclosporin A. It exhibited high-affinity binding to Mdr1 P-glycoprotein (P-gp) and demonstrated multidrug resistance-reversing activity superior to cyclosporin A and verapamil both in vitro and in vivo. Preclinical and phase I/II clinical data have indicated that plasma levels of PSC-833 with multidrug resistance-reversing activities are achievable. Potent inhibition of intestinal, hepatobiliary and blood-brain barrier P-gp function has been demonstrated. The toxicity profiles of valspodar are acceptable and dose-limited by transient and reversible cerebellar ataxia. It has shown multidrug resistance-modulating activities towards acute myeloid leukemia, multiple myeloma and ovarian cancer in phase I/II clinical trials. However, the company discontinued development of valspodar in April 2001 following disappointing results reported from several multicentre phase III studies.

CNS Activity

Curator's Comment: Also known to be CNS penetrant in mouse

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis.
2000 Jan 21
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
2003 Apr
Nickel-induced cell death and survival pathways in cultured renal proximal tubule cells: roles of reactive oxygen species, ceramide and ABCB1.
2014 Apr
Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.
2015 Jan 5
Patents

Patents

Sample Use Guides

2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
Route of Administration: Intravenous
In Vitro Use Guide
MDA/T0.3 cells were incubated in 1 mkM PSC-833 for 24 hours and the IC50 of taxol determined in the presence of PSC-833.
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:52:11 UTC 2023
Edited
by admin
on Sat Dec 16 15:52:11 UTC 2023
Record UNII
Q7ZP55KF3X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VALSPODAR
INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
VALSPODAR [MI]
Common Name English
valspodar [INN]
Common Name English
CYCLOSPORIN D, 6-((2S,4R,6E)-4-METHYL-2-METHYLAMINO)-3-OXO-6-OCTENOIC ACID)-
Common Name English
VALSPODAR [USAN]
Common Name English
CYCLO(((2S,4R,6E)-4-METHYL-2-(METHYLAMINO)-3-OXO-6-OCTENOYL)-L-VALYL-N-METHYLGLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYL-L-LEUCYL-L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL)
Common Name English
VALSPODAR [VANDF]
Common Name English
SDZ PSC 833
Code English
VALSPODAR [MART.]
Common Name English
SDZ-PSC 833
Code English
Valspodar [WHO-DD]
Common Name English
AMDRAY
Brand Name English
PSC833
Code English
Classification Tree Code System Code
NCI_THESAURUS C1744
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
Code System Code Type Description
CAS
121584-18-7
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
NCI_THESAURUS
C1405
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
EVMPD
SUB00018MIG
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
SMS_ID
100000079050
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
FDA UNII
Q7ZP55KF3X
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
MERCK INDEX
m11373
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY Merck Index
INN
7481
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
WIKIPEDIA
Valspodar
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
DRUG BANK
DB11869
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
MESH
C070272
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
PUBCHEM
5281884
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
ChEMBL
CHEMBL1086218
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
USAN
MM-11
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
EPA CompTox
DTXSID90873386
Created by admin on Sat Dec 16 15:52:12 UTC 2023 , Edited by admin on Sat Dec 16 15:52:12 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY